EFCCA is involved in an exciting new Horizon Europe project called FIBROTARGET. This project aims to validate novel immunotherapeutic targets against fibrosis in inflammatory bowel disease in order to obtain patients and regulatory approval for implementation of these novel noninvasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD. This will allow vital future therapeutic development for intestinal fibrosis by providing better molecular and clinical stratification of IBD patients at risk for fibrosis.
With FIBROTARGET, patients, researchers and clinicians can potentially look forward to novel immunotherapeutic drugs that aim to address intestinal fibrosis and fibrostenosis. Until now, therapies for IBD have only targeted inflammation. Even current treatments do not resolve the issue of how to predict who will develop fibrosis and strictures. So, contributions made from this European project will be certain to leave a promising legacy in health systems and outcomes, especially for those living with IBD.
The consortium comprises ten organisation participants with KU Leuven university as the lead partner to ensure effective dialogue and a continuous focus on the actual needs of patients living with IBD. EFCCA will also play an active role to ensure patients’ voices and insights are heard.
The FIBROTARGET project has received funding from the European Union’s Horizon Europe Research & Innovation programme under grant agreement No 101080523. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.